(Q36846711)

16 August 2017

1 reference

title

Beyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in Alzheimer's disease (English)

1 reference

16 August 2017

0 references

Norman R Relkin

1

1 reference

16 August 2017

1 June 2007

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

16 August 2017

1 reference

16 August 2017

7

1 reference

16 August 2017

735-748

1 reference

16 August 2017

6

1 reference

The cholinergic hypothesis of geriatric memory dysfunction

16 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Alzheimer's disease: the amyloid cascade hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Do cholinergic therapies have disease-modifying effects in Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Preclinical evidence of neuroprotection by cholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

What constitutes clinical evidence for neuroprotection in Alzheimer disease: support for the cholinesterase inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

PET imaging of brain acetylcholinesterase using [11C]CP-126,998, a brain selective enzyme inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Challenging the cholinergic system in mild cognitive impairment: a pharmacological fMRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Short-term rivastigmine treatment reduces EEG slow-wave power in Alzheimer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Short-term effects of acetylcholinesterase inhibitor treatment on EEG and memory performance in Alzheimer patients: an open, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Cholinergic markers in elderly patients with early signs of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: a double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Vitamin E and donepezil for the treatment of mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Effects of galantamine in patients with mild Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Abeta1-42 promotes cholinergic sprouting in patients with AD and Lewy body variant of AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Receptor-effector coupling dysfunctions in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Dementia with lewy bodies: findings from an international multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Effects of Donepezil on Cognitive Functioning in Down Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Efficacy and safety of donepezil in the treatment of executive dysfunction in Parkinson disease: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Donepezil in treatment-resistant bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Effects of rivastigmine on motor and cognitive impairment in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Donepezil for Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

The effect of Aricept in persons with persistent memory disorder following traumatic brain injury: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Donepezil medicated memory improvement in traumatic brain injury during post acute rehabilitation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury-clinical experience in 111 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Donepezil in vascular dementia: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Interaction with sigma(1) protein, but not N-methyl-D-aspartate receptor, is involved in the pharmacological activity of donepezil

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Antiamnesic and neuroprotective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide gas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Tacrine and donepezil attenuate the neurotoxic effect of A beta(25-35) in rat PC12 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Protective effect of donepezil against Abeta(1-40) neurotoxicity in rat septal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Comparison of donepezil and memantine for protective effect against amyloid-beta(1-42) toxicity in rat septal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Cerebral perfusional effects of cholinesterase inhibitors in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Changes in the rCBF images of patients with Alzheimer's disease receiving Donepezil therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Protective effect of donepezil in a primary culture of rat cortical neurons exposed to oxygen-glucose deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Acetylcholinesterase inhibitor ENA-713 protects against ischemia-induced decrease in pre- and postsynaptic cholinergic indices in the gerbil brain following transient ischemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Comparison of the effects of cholinesterase inhibitors on [3H]MK-801 binding in rat cerebral cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Protective effect of donepezil in primary-cultured rat cortical neurons exposed to N-methyl-d-aspartate (NMDA) toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Alzheimer patients treated with an AchE inhibitor show higher IL-4 and lower IL-1 beta levels and expression in peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

The acetylcholinesterase inhibitor, Donepezil, regulates a Th2 bias in Alzheimer's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Oxidative energy metabolism in Alzheimer brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

An in vivo study of phosphorus and glucose metabolism in Alzheimer's disease using magnetic resonance spectroscopy and PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Clinical Value of Neuroimaging in the Diagnosis of Dementia. Sensitivity and Specificity of Regional Cerebral Metabolic and Other Parameters for Early Identification of Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Brain-imaging surrogate markers for detection and prevention of age-related memory loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

N-acetylaspartate in neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

N-acetylaspartate and N-acetylaspartylglutamate levels in Alzheimer's disease post-mortem brain tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Randomized, Placebo-Controlled Trial of the Effects of Donepezil on Neuronal Markers and Hippocampal Volumes in Alzheimer’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Rates of hippocampal atrophy correlate with change in clinical status in aging and AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development--a study of molecular forms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Amyloid precursor protein in platelets of patients with Alzheimer disease: effect of acetylcholinesterase inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Cholinesterase inhibitor affects the amyloid precursor protein isoforms in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Excess "read-through" acetylcholinesterase attenuates but the "synaptic" variant intensifies neurodeterioration correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Alternative splicing and neuritic mRNA translocation under long-term neuronal hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Acetylcholinergic neurotransmission and the beta-amyloid cascade: implications for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Acetylcholinesterase-amyloid-beta-peptide interaction: effect of Congo Red and the role of the Wnt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.735

21 January 2018

Identifiers

DOI

10.1586/14737175.7.6.735

1 reference

16 August 2017

1 reference

PubMed ID

17561789